Adenoid Cystic Carcinoma Clinical Trial
Official title:
Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma
Verified date | November 2014 |
Source | Seoul National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Food and Drug Administration |
Study type | Interventional |
The purpose of this phase II study of TKI258 (Dovitinib) in adenoid cystic carcinoma is to evaluate the efficacy of TKI258 (Dovitinib).
Status | Completed |
Enrollment | 33 |
Est. completion date | November 2014 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed adenoid cystic carcinoma - Local, locally advanced or metastatic disease documented as having shown progression on a scan (CT, MRI, MIBI scan) taken 2 to 12 months prior to baseline compared to a previous scan taken at any time in the past. Progression must be documented according to RECIST criteria. - Disease that is not amenable to surgery, radiation or combined modality therapy with curative intent and who is previously treated with chemotherapy or local treatment (e.g. transarterial chemoembolization) - Presence of at least one measurable target lesion for further evaluation according to RECIST criteria - 18 years or older - ECOG performance status 0, 1 - Previous treatment with chemotherapy, targeted agents, loco-regional therapy (e.g. chemoembolization) are permitted providing that toxicity has resolved to < or = grade 1 at study entry and that last treatment was at least 4 weeks prior to baseline assessment. - Adequate organ function - A patient with the willingness to comply with the study protocol during the study period and capable of complying with it - A patient who signed the informed consent prior to the participation of the study and who understands that he or she has a right to withdrawal from participation in the study at any time without any disadvantages. Exclusion Criteria: - A patient with no measurable disease - Prior chemotherapy, radiation therapy or surgery within 4 weeks prior to study entry except palliative radiotherapy to non-target lesions (within 2 weeks prior to study entry) - A patient with previous active or passive immunotherapy - A patient with intestinal obstruction or impending obstruction, recent active upper GI bleeding - A pregnant or lactating patient - A patient of childbearing potential without being tested for pregnancy at baseline or with being tested for positive. (A postmenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential) - A man or woman of childbearing potential who has no willingness to use a contraceptive measure during the study - A patient with history of another malignant disease within past 5 years, except curatively treated basal cell carcinoma of skin and cervical carcinoma in situ. - A patient with history of uncontrolled seizures, central nervous system disorder or psychiatric disorders that are considered clinically significant by the investigator that would prohibit the understanding of informed consent or that may be considered to interfere with the compliance of the administration of the study medications. - A patient with clinically significant heart disease (e.g. congestive heart failure, symptomatic coronary artery diseases, cardiac arrhythmia, etc) or myocardial infarction within past 12 months. - Ongoing cardiac arrhythmia of grade > or = 2, atrial fibrillation of any grade, or QTc interval > 450 msec for males or > 470 msec for female. - A patient with interstitial pneumonia or diffuse symptomatic fibrosis of the lungs - A patient with peripheral neuropathy of grade 1 by NCI CTC, caused by other factors (e.g. alcohol, diabetes, etc). If the absence of deep tendon reflexes is the only neurologic disorder, this condition does not apply to the exclusion criteria. - A patient with organ transplantation requiring immunosuppressive therapy |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Department of Internal Medicine, Seoul National University Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | progression free survival | To determine 4month progression-free survival of TKI258 (Dovitinib) when administered as monotherapy in patients with unresectable adenoid cystic carcinoma | 4 month | No |
Secondary | overall survival | 2 years | No | |
Secondary | response rate | CT scan will be evaluated every 2 cycles (per 8 weeks)till progression. Reponse rate will be evaluated by RECIST criteria | 8 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04973683 -
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
|
Phase 1 | |
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05010629 -
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
|
Phase 2 | |
Recruiting |
NCT04801264 -
Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617
|
Early Phase 1 | |
Completed |
NCT03319641 -
PSMA-PET Imaging for Advanced ACC/SDC
|
N/A | |
Recruiting |
NCT02942693 -
Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma
|
Phase 2 | |
Completed |
NCT00581360 -
Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck
|
Phase 2 | |
Not yet recruiting |
NCT05553782 -
Drug Screening Using Novel IMD in ACC and Salivary Cancers
|
Early Phase 1 | |
Completed |
NCT04291300 -
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT02775370 -
A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
|
Phase 2 | |
Active, not recruiting |
NCT02780310 -
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
|
Phase 2 | |
Completed |
NCT04119453 -
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
|
Phase 2 | |
Active, not recruiting |
NCT02098538 -
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
|
Phase 2 | |
Completed |
NCT01524692 -
Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
|
Phase 2 | |
Completed |
NCT01558661 -
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
|
Phase 2 | |
Recruiting |
NCT03556228 -
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
|
Phase 1 | |
Not yet recruiting |
NCT06462183 -
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
|
Phase 1 | |
Recruiting |
NCT01192087 -
Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04209660 -
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
|
Phase 2 | |
Recruiting |
NCT05774899 -
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
|
Phase 1/Phase 2 |